Cargando…
Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management
Aromatase inhibitors are widely used as adjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer. While the agents are associated with slightly improved survival outcomes when compared to tamoxifen alone, bone and musculoskeletal side effects are substantial and often le...
Autores principales: | Gaillard, Stéphanie, Stearns, Vered |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219175/ https://www.ncbi.nlm.nih.gov/pubmed/21457526 http://dx.doi.org/10.1186/bcr2818 |
Ejemplares similares
-
Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer
por: Hertz, Daniel L., et al.
Publicado: (2021) -
Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management
por: Hyder, Tara, et al.
Publicado: (2021) -
Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study
por: Henry, N L, et al.
Publicado: (2010) -
Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors
por: Khan, Qamar J., et al.
Publicado: (2010) -
Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors
por: Park, Jin Young, et al.
Publicado: (2013)